Scientists at Washington State University, USA, have conducted a clinical trial to investigate the acute effect of cannabigerol on anxiety, stress, and mood in healthy individuals. They have published the trial findings in the journal Scientific Reports . Study: Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial .
Image Credit: Kyrylo Vasyliev / Shutterstock The global cannabis market is expanding rapidly because of the recent legalization of its recreational use in many countries. Although delta-9-tetrahydrocannabinol-enriched products are currently dominating the market, cannabis producers are aiming at isolating and marketing various minor phytocannabinoids and terpenes with the strong claim of their therapeutic potential. Among various non-intoxicating cannabinoids, cannabidiol continues to be the most preferred choice by both consumers and researchers.
Cannabigerol is another minor (non-intoxicating) phytocannabinoid that has gained popularity in recent times. Cannabigerol is a precursor of many other phytocannabinoids, including delta-9-tetrahydrocannabinol, cannabidiol, and cannabichromene. Thus, it is often regarded as the “mother of all cannabinoids.
” Several preclinical trials have highlighted cannabigerol's therapeutic activities, including antibiotic, antifungal, antihypertensive, antidepression, and analgesic properties. In this study, scientists have investigated the acute effect of cannabig.